Pharmacological inhibition of the soluble epoxide hydrolase-from mouse to man

Current Opinion in Pharmacology

Volumn 10, Issue 2, 2010, Pages 173-178

  Revermann, Marc ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPOXIDE HYDROLASE; EPOXIDE HYDROLASE INHIBITOR; EPOXYICOSATRIENOIC ACID; HYDROLASE INHIBITOR; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; AORTA ANEURYSM; APOPTOSIS; ATHEROSCLEROSIS; BRAIN INFARCTION; CARDIOVASCULAR EFFECT; CARDIOVASCULAR SYSTEM; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SPECIFICITY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME SUBSTRATE COMPLEX; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERTENSION; KIDNEY DISEASE; NONHUMAN; PAIN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; REVIEW; RISK BENEFIT ANALYSIS; SEPTIC SHOCK;

8,11,14-EICOSATRIENOIC ACID; ANIMALS; ARACHIDONIC ACIDS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; ENZYME INHIBITORS; EPOXIDE HYDROLASES; HUMANS; ISOMERISM; MODELS, BIOLOGICAL;

EID: 77949725653     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2009.12.002     Document Type: Review

References (48)

1. Spector A.A., Norris A.W. Action of epoxyeicosatrienoic acids on cellular function. Am J Physiol Cell Physiol 2007, 292:C996-1012.
2. Fang X., Weintraub N.L., Oltman C.L., Stoll L.L., Kaduce T.L., Harmon S., Dellsperger K.C., Morisseau C., Hammock B.D., Spector A.A. Human coronary endothelial cells convert 14,15-EET to a biologically active chain-shortened epoxide. Am J Physiol Heart Circ Physiol 2002, 283:H2306-H2314.
3. Chen J.K., Chen J., Imig J.D., Wei S., Hachey D.L., Guthi J.S., Falck J.R., Capdevila J.H., Harris R.C. Identification of novel endogenous cytochrome p450 arachidonate metabolites with high affinity for cannabinoid receptors. J Biol Chem 2008, 283:24514-24524.
4. Behm D.J., Ogbonna A., Wu C., Burns-Kurtis C.L., Douglas S.A. Epoxyeicosatrienoic acids function as selective, endogenous antagonists of native thromboxane receptors: identification of a novel mechanism of vasodilation. J Pharmacol Exp Ther 2009, 328:231-239.
5. Chen J., Capdevila J.H., Zeldin D.C., Rosenberg R.L. Inhibition of cardiac l-type calcium channels by epoxyeicosatrienoic acids. Mol Pharmacol 1999, 55:288-295.
6. Lee H.C., Lu T., Weintraub N.L., VanRollins M., Spector A.A., Shibata E.F. Effects of epoxyeicosatrienoic acids on the cardiac sodium channels in isolated rat ventricular myocytes. J Physiol 1999, 519:153-168.
7. Ng V.Y., Huang Y., Reddy L.M., Falck J.R., Lin E.T., Kroetz D.L. Cytochrome P450 eicosanoids are activators of peroxisome proliferator-activated receptor alpha. Drug Metab Dispos 2007, 35:1126-1134.
8. Yang S., Lin L., Chen J.X., Lee C.R., Seubert J.M., Wang Y., Wang H., Chao Z.R., Tao D.D., Gong J.P., Lu Z.Y., Wang D.W., Zeldin D.C. Cytochrome P-450 epoxygenases protect endothelial cells from apoptosis induced by tumor necrosis factor-alpha via MAPK and PI3K/Akt signaling pathways. Am J Physiol Heart Circ Physiol 2007, 293:H142-H151.
9. Node K., Huo Y., Ruan X., Yang B., Spiecker M., Ley K., Zeldin D.C., Liao J.K. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999, 285:1276-1279.
10. Dhanasekaran A., Al-Saghir R., Lopez B., Zhu D., Gutterman D.D., Jacobs E.R., Medhora M. Protective effects of epoxyeicosatrienoic acids on human endothelial cells from the pulmonary and coronary vasculature. Am J Physiol Heart Circ Physiol 2006, 291:H517-H531.
11. Michaelis U.R., Fisslthaler B., Barbosa-Sicard E., Falck J.R., Fleming I., Busse R. Cytochrome P450 epoxygenases 2C8 and 2C9 are implicated in hypoxia-induced endothelial cell migration and angiogenesis. J Cell Sci 2005, 118:5489-5498.
12. Hercule H.C., Schunck W.H., Gross V., Seringer J., Leung F.P., Weldon S.M., da Costa Goncalves A.C., Huang Y., Luft F.C., Gollasch M. Interaction between P450 eicosanoids and nitric oxide in the control of arterial tone in mice. Arterioscler Thromb Vasc Biol 2009, 29:54-60.
13. Imig J.D., Navar L.G., Roman R.J., Reddy K.K., Falck J.R. Actions of epoxygenase metabolites on the preglomerular vasculature. J Am Soc Nephrol 1996, 7:2364-2370.
14. Newman J.W., Morisseau C., Hammock B.D. Epoxide hydrolases: their roles and interactions with lipid metabolism. Prog Lipid Res 2005, 44:1-51.
15. Morisseau C., Hammock B.D. Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. Annu Rev Pharmacol Toxicol 2005, 45:311-333.
16. Chiamvimonvat N., Ho C.M., Tsai H.J., Hammock B.D. The soluble epoxide hydrolase as a pharmaceutical target for hypertension. J Cardiovasc Pharmacol 2007, 50:225-237.
17. Newman J.W., Morisseau C., Harris T.R., Hammock B.D. The soluble epoxide hydrolase encoded by EPXH2 is a bifunctional enzyme with novel lipid phosphate phosphatase activity. Proc Natl Acad Sci USA 2003, 100:1558-1563.
18. Fang X., Hu S., Watanabe T., Weintraub N.L., Snyder G.D., Yao J., Liu Y., Shyy J.Y., Hammock B.D., Spector A.A. Activation of peroxisome proliferator-activated receptor alpha by substituted urea-derived soluble epoxide hydrolase inhibitors. J Pharmacol Exp Ther 2005, 314:260-270.
19. Schmelzer K.R., Kubala L., Newman J.W., Kim I.H., Eiserich J.P., Hammock B.D. Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci USA 2005, 102:9772-9777.
20. Smith K.R., Pinkerton K.E., Watanabe T., Pedersen T.L., Ma S.J., Hammock B.D. Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. Proc Natl Acad Sci USA 2005, 102:2186-2191.
21. Revermann M., Barbosa-Sicard E., Dony E., Schermuly R.T., Morisseau C., Geisslinger G., Fleming I., Hammock B.D., Brandes R.P. Inhibition of the soluble epoxide hydrolase attenuates monocrotaline-induced pulmonary hypertension in rats. J Hypertens 2009, 27:322-331.
22. Parrish A.R., Chen G., Burghardt R.C., Watanabe T., Morisseau C., Hammock B.D. Attenuation of cisplatin nephrotoxicity by inhibition of soluble epoxide hydrolase. Cell Biol Toxicol 2009, 25:217-225.
23. Inceoglu B., Jinks S.L., Ulu A., Hegedus C.M., Georgi K., Schmelzer K.R., Wagner K., Jones P.D., Morisseau C., Hammock B.D. Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathways. Proc Natl Acad Sci USA 2008, 105:18901-18906.
24. Simpkins A.N., Rudic R.D., Schreihofer D.A., Roy S., Manhiani M., Tsai H.J., Hammock B.D., Imig J.D. Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection. Am J Pathol 2009, 174:2086-2095.
25. Koerner I.P., Zhang W., Cheng J., Parker S., Hurn P.D., Alkayed N.J. Soluble epoxide hydrolase: regulation by estrogen and role in the inflammatory response to cerebral ischemia. Front Biosci 2008, 13:2833-2841.
26. Fleming I., Michaelis U.R., Bredenkotter D., Fisslthaler B., Dehghani F., Brandes R.P., Busse R. Endothelium-derived hyperpolarizing factor synthase (Cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ Res 2001, 88:44-51.
27. Jung O., Brandes R.P., Kim I.H., Schweda F., Schmidt R., Hammock B.D., Busse R., Fleming I. Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension. Hypertension 2005, 45:759-765.
28. Loch D., Hoey A., Morisseau C., Hammock B.O., Brown L. Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase. Cell Biochem Biophys 2007, 47:87-98.
29. Huang H., Morisseau C., Wang J., Yang T., Falck J.R., Hammock B.D., Wang M.H. Increasing or stabilizing renal epoxyeicosatrienoic acid production attenuates abnormal renal function and hypertension in obese rats. Am J Physiol Renal Physiol 2007, 293:F342-F349.
30. Vriens J., Owsianik G., Fisslthaler B., Suzuki M., Janssens A., Voets T., Morisseau C., Hammock B.D., Fleming I., Busse R., Nilius B. Modulation of the Ca2 permeable cation channel TRPV4 by cytochrome P450 epoxygenases in vascular endothelium. Circ Res 2005, 97:908-915.
31. Ai D., Fu Y., Guo D., Tanaka H., Wang N., Tang C., Hammock B.D., Shyy J.Y., Zhu Y. Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Proc Natl Acad Sci USA 2007, 104:9018-9023.
32. Ng V.Y., Morisseau C., Falck J.R., Hammock B.D., Kroetz D.L. Inhibition of smooth muscle proliferation by urea-based alkanoic acids via peroxisome proliferator-activated receptor alpha-dependent repression of cyclin D1. Arterioscler Thromb Vasc Biol 2006, 26:2462-2468.
33. Sun J., Sui X., Bradbury J.A., Zeldin D.C., Conte M.S., Liao J.K. Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenase-derived eicosanoids. Circ Res 2002, 90:1020-1027.
34. Zhang L.N., Vincelette J., Cheng Y., Mehra U., Chen D., Anandan S.K., Gless R., Webb H.K., Wang Y.X. Inhibition of soluble epoxide hydrolase attenuated atherosclerosis, abdominal aortic aneurysm formation, and dyslipidemia. Arterioscler Thromb Vasc Biol 2009, 29:1265-1270.
35. Keseru B., Barbosa-Sicard E., Popp R., Fisslthaler B., Dietrich A., Gudermann T., Hammock B.D., Falck J.R., Weissmann N., Busse R., Fleming I. Epoxyeicosatrienoic acids and the soluble epoxide hydrolase are determinants of pulmonary artery pressure and the acute hypoxic pulmonary vasoconstrictor response. FASEB J 2008, 22:4306-4315.
36. Keseru B., Barbosa-Sicard E., Schermuly R.T., Tanaka H., Hammock B.D., Weissmann N., Fisslthaler B., Fleming I. Hypoxia-induced pulmonary hypertension: comparison of soluble epoxide hydrolase deletion vs. inhibition. Cardiovasc Res 2010, 85:232-240.
37. Li N., Liu J.Y., Timofeyev V., Qiu H., Hwang S.H., Tuteja D., Lu L., Yang J., Mochida H., Low R., Hammock B.D., Chiamvimonvat N. Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: insight gained using metabolomic approaches. J Mol Cell Cardiol 2009, 47:835-845.
38. Xu D., Li N., He Y., Timofeyev V., Lu L., Tsai H.J., Kim I.H., Tuteja D., Mateo R.K., Singapuri A., et al. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci USA 2006, 103:18733-18738.
39. Ai D., Pang W., Li N., Xu M., Jones P.D., Yang J., Zhang Y., Chiamvimonvat N., Shyy J.Y., Hammock B.D., Zhu Y. Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy. Proc Natl Acad Sci USA 2009, 106:564-569.
40. Hutchens M.P., Nakano T., Dunlap J., Traystman R.J., Hurn P.D., Alkayed N.J. Soluble epoxide hydrolase gene deletion reduces survival after cardiac arrest and cardiopulmonary resuscitation. Resuscitation 2008, 76:89-94.
41. Zhao X., Yamamoto T., Newman J.W., Kim I.H., Watanabe T., Hammock B.D., Stewart J., Pollock J.S., Pollock D.M., Imig J.D. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J Am Soc Nephrol 2004, 15:1244-1253.
42. Carroll M.A., Doumad A.B., Li J., Cheng M.K., Falck J.R., McGiff J.C. Adenosine2A receptor vasodilation of rat preglomerular microvessels is mediated by EETs that activate the cAMP/PKA pathway. Am J Physiol Renal Physiol 2006, 291:F155-F161.
43. Wei Y., Lin D.H., Kemp R., Yaddanapudi G.S., Nasjletti A., Falck J.R., Wang W.H. Arachidonic acid inhibits epithelial Na channel via cytochrome P450 (CYP) epoxygenase-dependent metabolic pathways. J Gen Physiol 2004, 124:719-727.
44. Fang X., Kaduce T.L., Weintraub N.L., Harmon S., Teesch L.M., Morisseau C., Thompson D.A., Hammock B.D., Spector A.A. Pathways of epoxyeicosatrienoic acid metabolism in endothelial cells. Implications for the vascular effects of soluble epoxide hydrolase inhibition. J Biol Chem 2001, 276:14867-14874.
45. Jiang J.G., Chen C.L., Card J.W., Yang S., Chen J.X., Fu X.N., Ning Y.G., Xiao X., Zeldin D.C., Wang D.W. Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. Cancer Res 2005, 65:4707-4715.
46. Burdon K.P., Lehtinen A.B., Langefeld C.D., Carr J.J., Rich S.S., Freedman B.I., Herrington D., Bowden D.W. Genetic analysis of the soluble epoxide hydrolase gene. EPHX2, in subclinical cardiovascular disease in the Diabetes Heart Study. Diab Vasc Dis Res 2008, 5:128-134.
47. Spiecker M., Darius H., Hankeln T., Soufi M., Sattler A.M., Schaefer J.R., Node K., Borgel J., Mugge A., Lindpaintner K., Huesing A., Maisch B., Zeldin D.C., Liao J.K. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation 2004, 110:2132-2136.
48. Davis B.B., Morisseau C., Newman J.W., Pedersen T.L., Hammock B.D., Weiss R.H. Attenuation of vascular smooth muscle cell proliferation by 1-cyclohexyl-3-dodecyl urea is independent of soluble epoxide hydrolase inhibition. J Pharmacol Exp Ther. 2006, 316:815-821.